Wallace Chris, Xue Ming-Zhan, Newhouse Stephen J, Marcano Ana Carolina B, Onipinla Abiodun K, Burke Beverley, Gungadoo Johannie, Dobson Richard J, Brown Morris, Connell John M, Dominiczak Anna, Lathrop G Mark, Webster John, Farrall Martin, Mein Charles, Samani Nilesh J, Caulfield Mark J, Clayton David G, Munroe Patricia B
Clinical Pharmacology and The Genome Centre, The William Harvey Research Institute, Barts and The London, Queen Mary's School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK.
Am J Hum Genet. 2006 Aug;79(2):323-31. doi: 10.1086/506370. Epub 2006 Jun 19.
Identification of the genetic influences on human essential hypertension and other complex diseases has proved difficult, partly because of genetic heterogeneity. In many complex-trait resources, additional phenotypic data have been collected, allowing comorbid intermediary phenotypes to be used to characterize more genetically homogeneous subsets. The traditional approach to analyzing covariate-defined subsets has typically depended on researchers' previous expectations for definition of a comorbid subset and leads to smaller data sets, with a concomitant attrition in power. An alternative is to test for dependence between genetic sharing and covariates across the entire data set. This approach offers the advantage of exploiting the full data set and could be widely applied to complex-trait genome scans. However, existing maximum-likelihood methods can be prohibitively computationally expensive, especially since permutation is often required to determine significance. We developed a less computationally intensive score test and applied it to biometric and biochemical covariate data, from 2,044 sibling pairs with severe hypertension, collected by the British Genetics of Hypertension (BRIGHT) study. We found genomewide-significant evidence for linkage with hypertension and several related covariates. The strongest signals were with leaner-body-mass measures on chromosome 20q (maximum LOD = 4.24) and with parameters of renal function on chromosome 5p (maximum LOD = 3.71). After correction for the multiple traits and genetic locations studied, our global genomewide P value was .046. This is the first identity-by-descent regression analysis of hypertension to our knowledge, and it demonstrates the value of this approach for the incorporation of additional phenotypic information in genetic studies of complex traits.
事实证明,确定基因对人类原发性高血压和其他复杂疾病的影响颇具难度,部分原因在于基因异质性。在许多复杂性状资源中,已收集了额外的表型数据,这使得共病中间表型可用于刻画基因上更具同质性的亚组。分析协变量定义亚组的传统方法通常依赖于研究人员先前对共病亚组定义的预期,这会导致数据集变小,同时功效也会降低。另一种方法是在整个数据集中检验基因共享与协变量之间的依赖性。这种方法的优点是能利用完整的数据集,并且可广泛应用于复杂性状的基因组扫描。然而,现有的最大似然方法在计算上可能极其昂贵,特别是因为通常需要进行排列检验来确定显著性。我们开发了一种计算强度较小的计分检验,并将其应用于英国高血压遗传学(BRIGHT)研究收集的2044对患有严重高血压的同胞对的生物统计学和生化协变量数据。我们发现了与高血压及若干相关协变量连锁的全基因组显著证据。最强的信号出现在20号染色体上与较瘦体重测量相关的区域(最大对数优势比 = 4.24)以及5号染色体上与肾功能参数相关的区域(最大对数优势比 = 3.71)。在对所研究的多个性状和基因位置进行校正后,我们的全基因组P值为0.046。据我们所知,这是首次对高血压进行基于血缘关系的回归分析,它证明了这种方法在复杂性状基因研究中纳入额外表型信息的价值。